- **1** Supplementary Materials
- 2

3 **Results**

4 Table S1. Data summary of direct antigen rapid test (DART) for detection of SARS-CoV-2
5 nucleocapsid protein and DART for detection of SARS-CoV-2 spike glycoprotein
6 performance in comparison to qRT-PCR results.

7

8 Table S2. Summary of results of COVID-19 outcomes in 3 US Regions and Brazil as a result 9 of Frequent Rapid Testing Protocol using SIDHRE-Q Model. Total Infected, Maximum 10 Hospitalized, and Total Deaths are shown for Massachusetts, Los Angeles, New York, and São 11 Jose do Rio Preto, Brazil under a qRT-PCR protocol (symptomatic testing) and a Rapid Testing 12 protocol (once every three days with test performance of 80% sensitivity and 90% specificity). 13

Table S3. Demographic and clinical summary of patients evaluated by the SARS-CoV-2
Direct Antigen Rapid Test (DART). N response, N or mean of positive, and % or standard
deviation for each group is presented. All samples (n=131) collected and tested in São José do
Rio Preto, Brazil.

18

Figure S1. Graphical scheme displaying the relationships between the stages of quarantine
and infection in *SIDHRE-Q* model: Q-U, quarantine uninfected; S, susceptible (uninfected); I,
infected undetected (pre-testing and infected); D, infected detected (infection diagnosis through
testing); H, hospitalized (infected with life threatening symptom progression); R, recovered

(healed); E, extinct (dead); and Q-R, quarantine recovered (healed but in quarantine by false
positive testing).

25

26 Figure S2. COVID-19 Outcomes as a result of Frequent Rapid Testing Protocol with 27 variable test performances using SIDHRE-Q Model. The Cumulative Detected Infected, 28 Hospitalized, Deceased, Active Infections, Recovered, and Quarantined are modeled over 105 29 days (top to bottom) using reported data from 4 global regions: Massachusetts, Los Angeles, New York City, and São José do Rio Preto in Brazil (left to right). The COVID-19 population 30 31 spread and outcomes are modeled under a Rapid Testing Protocol with variable testing 32 frequencies ranging from 1-21 days between tests, and variable test performances: 90% 33 specificity with 90% sensitivity (A), 70% sensitivity (B), 50% sensitivity (C), and 30% 34 sensitivity (D); and 80% specificity with 90% sensitivity (E), 70% sensitivity (F), 50% sensitivity (G), and 30% sensitivity (H). This protocol is compared to a symptom-based Rapid 35 36 Testing protocol and a symptom-based qRT-PCR protocol. 37 38 Figure S3. Effect of Rapid Testing Protocol under variable testing sensitivities and 39 increasing frequency under the SIDHRE-Q Model. The Cumulative Infections, Maximum 40 Simultaneously Hospitalized, and Deceased populations are modeled for Massachusetts, Los 41 Angeles, New York City, and São José do Rio Preto in Brazil. The effect of increasing frequency 42 of testing is modeled for various testing sensitivities (30%-90%) with an 80% specificity. 43 44 Figure S4. Effect of County Based Rapid Testing strategy on COVID-19 outcomes in 45 California. This protocol varies testing frequency in accordance to the number of recorded

46 cases; the threshold for number of active infections which, if reached, signals to commence 47 everyday testing, the highest frequency considered. A Rapid Test with a 80% sensitivity and 48 90% sensitivity is used in this deployment strategy. Shown is the total cost per person per day 49 versus the cumulative infections, maximum simultaneously hospitalized, and cumulative deaths 50 with varied thresholds for all of CA is shown. The County Based Rapid Testing strategy is 51 compared to uniform testing, which distributes the same number of total tests used in the county strategy, albeit evenly across each county. The effects of uniform testing are modeled for both a 52 Rapid Testing protocol and a qRT-PCR protocol. 53

54

Figure S5. Time series of the four fitted parameters α , ν , μ , and τ (left to right) for MA, LA, NYC, and SJRP (top to bottom). See Table 2 in the Methods section for an explanation of the parameters. The values are extracted every seven days from data provided by the respective regions. The parameters vary significantly over time and location. Flat points occur during the seven day windows where the parameters are held constant. The fitting procedure is also outlined in the Methods section.

61

62

63 Figure S6. Time series of the three fitted pieces of data Cumulative Cases, Daily

64 Hospitalized, and Cumulative Deaths (left to right) for each county receiving testing in CA;

- 65 Ventura (2A), Stanislaus (2B), Santa Clara (2C), San Joaquin (2D), San Francisco (2E), San
- 66 Diego (2F), San Bernardino (2G), Sacramento (2H), Orange (2I), Los Angeles (2J), Kern (2K),
- 67 Fresno (2L), Alameda (2M). The counties included satisfy two requirements: population greater

68	than 1.5% of the total CA	po	pulation and	1 nonzero	total	number	of d	eaths	at each	point	in t	ime.
00		·ρυ	pulation and		ioiui	numoer	UI U	cuillo	at cucii	point		

69 The fitting procedure is outlined in the Methods section.

- .

- _ .

- ~ ~

91 Supplementary Tables

93	Table S1. Data summary of direct antigen rapid test (DART) for detection of SARS-CoV-2
94	nucleocapsid protein and DART for detection of SARS-CoV-2 spike glycoprotein
95	performance in comparison to qRT-PCR results.
96	
97	
98	
99	

Cycle threshold (Ct) value	Total Cases	DART Positives	DART Negatives	Sensitivity	95% Confidence Interval (semi- interval)	Specificity	95% Confidence Interval (semi- interval)	Positive Predictive Value (PPV)	Negative Predictive Value (NPV)	Prevalence	Overall Agreement
	114	24	06	95.8%	4.6%	91.1%	2.9%	74.2%	%8'86	21.1%	92.1%
	143	53	06	90.6%%	3.9%	91.1%	2.9%	85.7%	94.3%	37.1%	90.9%
	168	78	06	83.3%%	4.1%	91.1%	2.9%	89.0%	86.3%	46.4%	87.5%
	189	66	06	79.8%%	3.9%	91.1%	2.9%	90.8%	80.4%	52.4%	85.2%
	190	100	90	80.0%%	3.9%	91.1%	2.9%	90.9%	80.4%	52.6%	85.3%
	51	2	49	100.0%	20.9%	85.7%	4.9%	22.2%	%6'86	3.9%	86.3%
	72	23	49	100.0%	2.8%	85.7%	4.9%	76.7%	98.9%	31.9%	90.3%
	06	41	49	97.6%	2.8%	85.7%	4.9%	85.1%	96.6%	45.6%	91.1%
	111	62	49	91.9%	3.4%	85.7%	4.9%	89.1%	89.4%	55.9%	89.2%
< 30	121	72	49	84.7%	4.1%	85.7%	4.9%	89.7%	79.2%	59.5%	85.1%
< 35	121	72	49	84.7%	4.1%	85.7%	4.9%	89.7%	79.2%	59.5%	85.1%

Table S2. Summary of results of COVID-19 outcomes in 3 US Regions and Brazil as a result
of Frequent Rapid Testing Protocol using SIDHRE-Q Model. Total Infected, Maximum
Hospitalized, and Total Deaths are shown for Massachusetts, Los Angeles, New York, and São
Jose do Rio Preto, Brazil under a qRT-PCR protocol (symptomatic testing) and a Rapid Testing
protocol (once every three days with test performance of 80% sensitivity and 90% specificity).

		Massac	husetts	Los A	ngeles	New Yo	ork City	São Jo Rio Pret	osé do o, Brazil
		qRT-PCR	1 per 3 days	qRT-PCR	1 per 3 days	qRT-PCR	1 per 3 days	qRT-PCR	1 per 3 days
Total Ir	nfected	18.40%	1.60%	11.70%	1.42%	26.40%	9.45%	11.70%	0.186%
Hospi	Max italized	0.056%	0.025%	0.028%	0.022%	0.144%	0.130%	0.054%	0.003%
Total I	Deaths	0.119%	0.029%	0.039%	0.009%	0.226%	0.157%	0.040%	0.003%
							·		

120 Table S3


121 Table S3. Demographic and clinical summary of patients evaluated by the SARS-CoV-2 Direct

122 Antigen Rapid Test (DART). N response, N or mean of positive, and % or standard deviation for each

- 123 group is presented. All samples (n=131) collected and tested in São José do Rio Preto, Brazil.

		TOTAL		CO	VID-19 posit	ive	COV	/ID-19 nega	ative
	N response	N or <i>mean</i> of positive	% or standard deviation	N response	N or <i>mean</i> of positive	% or standard deviation	N response	N or <i>mean</i> of positive	% or standard deviation
Age	121	40.43	17.17	72	43.37	12.58	49	36.12	15.3
0-14 yr	121	5	4.1%	72	2	2.8%	49	3	6.1%
15-29 yr	121	30	24.8%	72	17	23.6%	49	13	26.5%
30-59 yr	121	69	57.0%	72	39	54.2%	49	30	61.2%
≥60 yr	121	17	14.0%	72	14	19.4%	49	3	6.1%
Gender									
Female	121	75	62.0%	72	43	59.7%	49	32	65.3%
Male	121	46	38.0%	72	29	40.3%	49	17	34.7%
Comorbidities									
Cardiovascular disease	115	7	6.1%	71	6	8.5%	44	1	2.3%
Diabetes	115	9	7.8%	71	6	8.5%	44	3	6.8%
Asthma	115	1	0.9%	71	1	1.4%	44	0	0.0%
Pulmonary disease	115	4	3.5%	71	1	1.4%	44	3	6.8%
Chronic Kidney disease (Stage III, IV, V	115	12	10.4%	71	1	1.4%	44	11	25.0%
Immunosuppression	115	3	2.6%	71	1	1.4%	44	0	0.0%
Post pregnant	115	2	1.7%	71	1	1.4%	44	1	2.3%
Neurologic Disease	115	0	0.0%	71	0	0.0%	44	0	0.0%
Chromosomal disease	115	0	0.0%	71	0	0.0%	44	0	0.0%
Hematological diseases	115	0	0.0%	71	0	0.0%	44	0	0.0%
Liver disease	115	0	0.0%	71	0	0.0%	44	0	0.0%
Obesity	115	0	0.0%	71	0	0.0%	44	0	0.0%
Hospitalization	116	5	4.3%	71	5	7.0%	45	0	0.0%
Asymptomatic	116	8	6.9%	71	6	8.5%	45	2	4.4%
Inititial symptoms									
Fever	116	40	34.5%	71	32	45.1%	45	8	17.8%
Cough	116	66	56.9%	71	42	59.2%	45	24	53.3%
Sore throat	116	47	40.5%	71	22	31.0%	45	25	55.6%
Dyspnea	116	25	21.6%	71	17	23.9%	45	8	17.8%
Low Saturation	116	4	3.5%	71	4	5.7%	45	0	0.0%
Diarrhea	116	4	3.5%	71	4	5.7%	45	0	0.0%
Vomit	116	3	2.6%	71	2	2.9%	45	1	2.2%
Headache	116	43	37.4%	71	28	40.0%	45	15	33.3%
Days of fever/symptoms	120	3.23	2.64	71	3.29	2.46	49	3.14	2.9


- 131 Supplementary Figures
- 132 Figure S1
- 133 Figure S1. Graphical scheme displaying the relationships between the stages of quarantine and
- 134 infection in *SIDHRE-Q* model: Q-U, quarantine uninfected; S, susceptible (uninfected); I, infected
- 135 undetected (pre-testing and infected); **D**, infected detected (infection diagnosis through testing); **H**,
- 136 hospitalized (infected with life threatening symptom progression); **R**, recovered (healed); **E**, extinct
- 137 (dead); and Q-R, quarantine recovered (healed but in quarantine by false positive testing).




149 Figure S	2
--------------	---

150	Figure S2. COVID-19 Outcomes as a result of Frequent Rapid Testing Protocol with variable test
151	performances using SIDHRE-Q Model. The Cumulative Detected Infected, Hospitalized, Deceased,
152	Active Infections, Recovered, and Quarantined are modeled over 105 days (top to bottom) using reported
153	data from 4 global regions: Massachusetts, Los Angeles, New York City, and São José do Rio Preto in
154	Brazil (left to right). The COVID-19 population spread and outcomes are modeled under a Rapid Testing
155	Protocol with variable testing frequencies ranging from 1-21 days between tests, and variable test
156	performances: 90% specificity with 90% sensitivity (A), 70% sensitivity (B), 50% sensitivity (C), and
157	30% sensitivity (D); and 80% specificity with 90% sensitivity (E), 70% sensitivity (F), 50% sensitivity
158	(G), and 30% sensitivity (H). This protocol is compared to a symptom-based Rapid Testing protocol and
159	a symptom-based qRT-PCR protocol.
160	
161	
162	
163	
164	
165	
166	
167	
168	
169	
170	
171	
172	






Sensitivity: 90.0% Specificity: 90.0%




Sensitivity: 70.0% Specificity: 90.0%

177 C




178


Sensitivity: 50.0% Specificity: 90.0%




Sensitivity: 30.0% Specificity: 90.0%




Sensitivity: 90.0% Specificity: 80.0%



Sensitivity: 70.0% Specificity: 80.0%








Sensitivity: 30.0% Specificity: 80.0%

- 190 Figure S3
- 191 Figure S3. Effect of Rapid Testing Protocol under variable testing sensitivities and increasing
- 192 **frequency under the** *SIDHRE-Q* **Model.** The Cumulative Infections, Maximum Simultaneously
- 193 Hospitalized, and Deceased populations are modeled for Massachusetts, Los Angeles, New York City,
- and São José do Rio Preto in Brazil. The effect of increasing frequency of testing is modeled for various
- testing sensitivities (30%-90%) with an 80% specificity.
- 196






200 Figure S4

201 Figure S4. Effect of County Based Rapid Testing strategy on COVID-19 outcomes in California.

- 202 This protocol varies testing frequency in accordance to the number of recorded cases; the threshold for
- 203 number of active infections which, if reached, signals to commence everyday testing, the highest
- frequency considered. A Rapid Test with a 80% sensitivity and 90% sensitivity is used in this deployment
- strategy. Shown is the total cost per person per day versus the cumulative infections, maximum
- simultaneously hospitalized, and cumulative deaths with varied thresholds for all of CA is shown. The
- 207 County Based Rapid Testing strategy is compared to uniform testing, which distributes the same number
- of total tests used in the county strategy, albeit evenly across each county. The effects of uniform testing
- are modeled for both a Rapid Testing protocol and a qRT-PCR protocol.
- 210



- 212
- 213
- _ . .
- 214
- 215
- 216
- 217
- 218
- 219

220 Figure S5


221 Figure S5. Time series of the four fitted parameters α , ν , μ , and τ (left to right) for MA, LA, NYC, and

SJRP (top to bottom). See Table 3 in the Methods section for an explanation of the parameters. The


values are extracted every seven days from data provided by the respective regions. The parameters vary

significantly over time and location. Flat points occur during the seven day windows where the

225 parameters are held constant. The fitting procedure is also outlined in the Methods section.




- 228 Figure S6
- 229 Figure S6. Time series of the three fitted pieces of data Cumulative Cases, Daily Hospitalized, and
- 230 Cumulative Deaths (left to right) for each county receiving testing in CA; Ventura (2A), Stanislaus (2B),
- 231 Santa Clara (2C), San Joaquin (2D), San Francisco (2E), San Diego (2F), San Bernardino (2G),
- 232 Sacramento (2H), Orange (2I), Los Angeles (2J), Kern (2K), Fresno (2L), Alameda (2M). The counties
- 233 included satisfy two requirements: population greater than 1.5% of the total CA population and nonzero
- total number of deaths at each point in time. The fitting procedure is outlined in the Methods section.
- 235
- 236 A






B



- 239
- 240
- 241











D






E











G








Η




254













260 K

